about
Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological MalignanciesAge and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse.Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersBortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.Angiogenesis and progression in human melanoma.Circulating miRNA markers show promise as new prognosticators for multiple myeloma.Vascular endothelial growth factor and its receptors in multiple myeloma.Multiple myeloma macrophages: pivotal players in the tumor microenvironment.Role of hematopoietic growth factors in angiogenesis.Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignanciesMast cell contribution to angiogenesis related to tumour progression.Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases.Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.Evidence for bone marrow adult stem cell plasticity: properties, molecular mechanisms, negative aspects, and clinical applications of hematopoietic and mesenchymal stem cells transdifferentiation.Neutropenia and G-CSF in lymphoproliferative diseases.Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.Managing myelodysplastic symptoms in elderly patients.Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Identify multiple myeloma stem cells: Utopia?Metronomic chemotherapy from rationale to clinical studies: a dream or reality?Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells. Novel evidence of the occurrence of NAD(P)H oxidase activity.Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression.Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis.
P50
Q26770838-1BC94370-0162-4257-B7D1-31354A1EE21AQ30595175-B3EB194F-4D22-4188-8D15-456E091E3697Q33241652-0D1B546D-DC84-49D8-9DDA-49651DDE473AQ33292668-732B3018-12EC-4D8D-AAE7-1FE0DCDEF696Q33387332-0D2197CE-A4E3-4AF7-ABF7-2216328B51B6Q33395312-25969ED3-B39C-44B8-9E19-589EF740F6A9Q33398019-40FFB5C9-4F7A-4A5A-BC08-5DF2880AD737Q33412804-A7D165B1-29AF-4226-B7B4-ACAA3CE19D26Q33982978-F2A74450-3D71-4E20-86CE-A91449BCD1A8Q34135498-809A31C7-5C68-4BC9-8622-5DD07683E2E8Q34265556-8B911DED-BDB7-45B4-9130-210B9B72E96DQ34329152-62C6AFF6-E32E-4718-95A0-1578C24A8A87Q34508938-823A40D1-9986-468E-B6FC-C4BC3FC6AA20Q34508946-B6320343-66E5-44E2-8ACA-95EF5A24E485Q35547153-8CBE74C4-E6A5-4BBD-B56F-D2447222E9F9Q35950541-C3CAC0EF-9905-451D-8B05-0B5CF58F8754Q36048128-366BE075-822F-4236-933A-055029855CD4Q36117230-B0809BD8-C569-4413-B85E-E0AC5209A391Q36618269-6AB18979-8F0D-4782-B120-95130549D3E2Q36763484-333AEC84-5137-4D54-A5E3-667DFB56080DQ36828921-CADE818A-E8B0-4852-A250-55D5D0C2D034Q37046655-86B6E772-3856-43AF-8B02-185C89D8F65EQ37448906-32129A87-B793-4149-853C-54FF7DFD3390Q38086121-9FD5E172-6368-418E-8767-3B788E60A52CQ38261677-0E26C765-50D8-4A2C-B9CF-031D8A08E1A3Q38332486-324B8C16-D233-4796-AECE-165DD0819CC3Q38346010-D02BAB8E-ECA7-4D14-B045-7A1A028B916EQ39070193-62F91162-555B-46FF-BC83-8CFACAAF4000Q39071875-0BE6A163-C7EA-4467-91B9-F8A167ADEF2EQ39134426-B08C6366-EA27-4831-9FAB-24A7B72917E6Q39305373-5A590042-A07A-4295-A564-A499EDFD9E49Q40095723-1CD2ECFB-6C89-4BCB-AC73-A756238A54FEQ40408326-EAB86D16-3890-4EFD-A97A-1D8DE740D233Q40424738-5BA3AA0E-58F3-4FC3-945B-B7541DAF5836Q40438264-E77B27F3-E96F-46E6-BBA6-B48B5213BFCAQ40485837-4C4BDE8A-FFC9-4545-80E9-D319E1BF11FDQ40839677-FD008AB0-6AF2-47B3-9C8E-637D23B822C2Q40899348-79BDBB24-5FCB-4080-AE92-3EDA1B3F6010Q40962410-014B2C96-48F0-4B9E-BFB1-BDA9D558B5CCQ41041796-D7B239BC-FD58-4CF4-88AE-C98781D99548
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberto Ria
@ast
Roberto Ria
@en
Roberto Ria
@es
Roberto Ria
@nl
Roberto Ria
@sl
type
label
Roberto Ria
@ast
Roberto Ria
@en
Roberto Ria
@es
Roberto Ria
@nl
Roberto Ria
@sl
prefLabel
Roberto Ria
@ast
Roberto Ria
@en
Roberto Ria
@es
Roberto Ria
@nl
Roberto Ria
@sl
P1053
I-4263-2015
P106
P1153
6701590838
P21
P31
P3829
P3835
roberto-ria
P496
0000-0002-1515-0090